AT
Atara Biotherapeutics, Inc.
ATRA · NASDAQ
$8.93 -5.25% (-$0.50)
1M -0.85%
Market Cap $87.5M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$9.73
9.0% upside
Current Price
$8.93
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ATRA is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/S 14.12x
P/FCF N/A
P/B N/A
Growth
100 /100
Growing Rev. growth 23.85%
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak FCF margin 353.49%
Op. margin 229.67%
Gross margin 91.38%
Quality
5 /100
Poor ROA 79.38%
Asset turnover 0.29x
ROIC 93.30%
Debt
42 /100
Moderate Int. coverage -4.90x
Current ratio 1.98x
Net debt/EBITDA N/A
Stability
6 /100
Unstable Profitable years 1
EPS volatility 71.55%
Beta 0.09x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ATRA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Anhco Nguyen
Employees
10
Headquarters
Thousand Oaks
Upcoming events
11 NOV
Earnings
Upcoming earnings report